Three Rivers Pharmaceuticals, LLC

11 articles about Three Rivers Pharmaceuticals, LLC

• Kadmon Pharmaceuticals Acquires Three Rivers Pharmaceuticals, LLC For More Than $100 Million

  11/1/2010

• Three Rivers Pharmaceuticals, LLC Announces FDA Approval Of Expanded Labeling of INFERGEN(R)

  7/6/2010

• Three Rivers Pharmaceuticals, LLC Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

  6/16/2009

• Three Rivers Pharmaceuticals, LLC Improves Global Distribution Efficiency, Productivity by more than 50 Percent with TAKE Supply Chain

  5/12/2009

• Three Rivers Pharmaceuticals, LLC Obtains Additional Commercial Rights to Infergen(R) from Amgen (JOBS)

  9/17/2008

• Three Rivers Pharmaceuticals, LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals International for $91M

  1/15/2008

• Valeant Pharmaceuticals International Sells Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals, LLC for $91 Million

  12/20/2007

• Three Rivers Pharmaceuticals, LLC Protects Its Intellectual Property

  6/7/2007

• Samaritan Pharmaceuticals, Inc. In-Licenses Greece & Cyprus Marketing Rights For Amphocil From Three Rivers Pharmaceuticals, LLC

  12/14/2005

• Par Pharmaceutical Companies, Inc.'s Partner Receives Final Approval To Market Ribavirin Tablets

  12/5/2005

• FDA Announces Three Rivers Pharmaceuticals, LLC Tentative Approval Of Ribasphere(R) (Ribavirin, USP) Tablets

  10/24/2005